EU Member States, Industry Not Ready Yet For New Clinical Trials Regime
This article was originally published in The Pink Sheet Daily
With less than two years to go before implementation of the new EU Clinical Trials Regulation, there is a divergence of approaches amongst member states and some ignorance amongst trial sponsors.
You may also be interested in...
Europe’s parliamentarians have unsurprisingly and overwhelmingly voted in favor of the Clinical Trials Regulation – but implementation and transparency problems hover on the horizon.
MHRA’s Beneficial EU Relationship And Profitable Synergies With NICE: An Interview With Michael Rawlins
In December, Michael Rawlins was appointed head of the U.K.’s Medicines and Healthcare products Regulatory Agency. He recognizes the MHRA’s mutually beneficial relationship with European counterparts and is looking to safeguard synergies with other national regulatory bodies and NICE.
The EMA has recommended suspension of some 700 drug formations linked with Indian clinical trials company GVK Biosciences, but assures national agencies that this won’t result in shortages or safety issues.